
Search
Filter Results
Displaying 91–100 of 1070 results
-
Oct 29, 2024
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
The 36-participant trial will take place at multiple sites in Australia.
-
Oct 25, 2024
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Oct 25, 2024
Eye on the Cure Podcast | Episode 75: Sharon King
Sharon King, co-founder and president of Taylor’s Tale, talks to host Ben Shaberman about her family’s journey when her daughter Taylor was diagnosed with Batten disease.
-
Ongoing Foundation Fighting Blindness national webinars around the latest research for blinding diseases.
-
Oct 23, 2024
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Merger will provide additional capital for gene therapy development.
-
The Foundation’s grants and awards are critical and allow recipients to secure additional and often larger awards from other funding entities like the National Institute of Health.
-
Over the next five years, our focus is to raise awareness of our science initiatives, both within and outside the Foundation, particularly around our research portfolio.
-
To make a bigger impact on our mission to turn early research into clinical trials for people with IRDs and dry AMD, the Foundation will grow its network of collaborators and partners.
-
After a review by our Scientific Advisory Board (SAB), three key research gaps were identified: models to study retinal diseases, understanding how the immune system reacts, and finding biomarkers that can predict disease progression and help guide treatment decisions.
-
The fiscal year 2025-2029 Science Strategic Plan is developed with a single, overarching goal: To drive research projects and activities to overcome barriers to translating preclinical research into clinical trials for individuals affected by inherited retinal diseases and dry AMD.